Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options

References

• King TE Jr., Tooze JA, Schwarz MI, et al. Predicting survival in Idiopathic Pulmonary Fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1171–1181.
   PubMed Web of Science ®Google Scholar
• Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Collard HR, Pardo A, et al. Idiopathic Pulmonary Fibrosis. Nat Rev Dis Primers. 2017 Oct 20;3(1):17074.
   PubMedGoogle Scholar
• Ley B, Collard HR, Talmadge E, et al. Clinical course and prediction of survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Prednisone, Azathioprine. N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
   PubMed Web of Science ®Google Scholar
• King TE, Bradford WZ, Castro-Bernardini S, et al., A phase 3 trial of pirfenidone in patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014;370(22): 2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2014 May 29;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of Idiopathic Pulmonary Fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–e19.
   PubMed Web of Science ®Google Scholar
• Margaritopoulos GA, Trachalaki A, Wells AU, et al. Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulm Med. 2018 Nov 23;18(1):177.
   PubMedGoogle Scholar
• Canestaro WJ, Forrester SH, Raghu G, et al. Drug treatment of Idiopathic Pulmonary Fibrosis: systematic review and network meta-analysis. Chest. 2016 Mar;149(3):756–766.
   PubMed Web of Science ®Google Scholar
• Trawinska MA, Rupesinghe RD, Hart SP. Patient considerations and drug selection in the treatment of Idiopathic Pulmonary Fibrosis. Ther Clin Risk Manag. 2016;12:563–574.
   PubMed Web of Science ®Google Scholar
• Haynes RB, Devereaux PJ, Guyatt GH. Clinical expertise in the era of evidence-based medicine and patient choice. ACP J club 2002 Mar-Apr;136(2):A11–4.
   PubMedGoogle Scholar
• Chewning B, Sleath B. Medication decision-making and management: a client-centered model. Soc Sci Med. 1996 Feb;42(3):389–398.
   PubMed Web of Science ®Google Scholar
• Lasky J. Pirfenidone. IDrugs. 2004 Feb;7(2):166–172.
   PubMed Web of Science ®Google Scholar
• Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014 Jul;16(58):13–19.
   Google Scholar
• Azuma A, Nukiwa T, Tsuboi E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2005 May 1;171(9):1040–1047.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in Idiopathic Pulmonary Fibrosis. Eur Respir J. 2010 Apr;35(4):821–829.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with Idiopathic Pulmonary Fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21;377(9779):1760–1769.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in Idiopathic Pulmonary Fibrosis. Lancet Respir Med. 2017 Jan;5(1):33–41.
   PubMed Web of Science ®Google Scholar
• Ley B, Swigris J, Day BM, et al. Pirfenidone reduces respiratory-related hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 Sep 15;196(6):756–761.
   PubMed Web of Science ®Google Scholar
• Salih GN, Shaker SB, Madsen HD, et al. Pirfenidone treatment in Idiopathic Pulmonary Fibrosis: nationwide Danish results. Eur Clin Respir J. 2016;3(1):32608.
   PubMed Web of Science ®Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for Idiopathic Pulmonary Fibrosis. J Clin Med. 2016 2; 5(9): Sep.
   Web of Science ®Google Scholar
• Shi S, Wu J, Chen H, et al. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol. 2007 Oct;47(10):1268–1276.
   PubMed Web of Science ®Google Scholar
• Rubino CM, Bhavnani SM, Ambrose PG, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009 Aug;22(4):279–285.
   PubMed Web of Science ®Google Scholar
• Hostettler KE, Zhong J, Papakonstantinou E, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with Idiopathic Pulmonary Fibrosis. Respir Res. 2014 12; Dec(15): 157.
   Google Scholar
• Sato S, Shinohara S, Hayashi S, et al. Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respir Res. 2017 Sep 15;18(1):172.
   PubMedGoogle Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014 May;349(2):209–220.
   PubMed Web of Science ®Google Scholar
• Tandon K, Herrmann F, Ayaub E, et al. Nintedanib Attenuates the Polarization of Profibrotic Macrophages Through the Inhibition of Tyrosine Phosphorylation on CSF1 Receptor. A72. MECHANISMS DRIVING FIBROSIS. Am Thorac Soc Int Conf Abstr: Am Thorac Soc. 2017; A2397–A2397. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2397
   Google Scholar
• Morizumi S, Sato S, Abe S, et al. Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity. Eur Respir J. 2016;48(suppl 60):PA778.
   Google Scholar
• Richeldi L, Cottin V, Du Bois RM, et al. Nintedanib in patients with Idiopathic Pulmonary Fibrosis: combined evidence from the TOMORROW and INPULSIS((R)) trials. Respir Med. 2016 Apr;113:74–79.
   PubMed Web of Science ®Google Scholar
• Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with Idiopathic Pulmonary Fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1):e000397.
   PubMed Web of Science ®Google Scholar
• Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of Idiopathic Pulmonary Fibrosis: a population-based study. Chest. 2010 Jan;137(1):129–137.
   PubMed Web of Science ®Google Scholar
• Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with Idiopathic Pulmonary Fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan;7(1):60–68.
   PubMed Web of Science ®Google Scholar
• Corte T, Bonella F, Crestani B, et al. Safety, tolerability and appropriate use of nintedanib in Idiopathic Pulmonary Fibrosis. Respir Res. 2015;16(1):116.
   PubMedGoogle Scholar
• Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in Idiopathic Pulmonary Fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med. 2016 Jan 15;193(2):178–185.
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for Idiopathic Pulmonary Fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243.
   PubMed Web of Science ®Google Scholar
• Brown KK, Flaherty KR, Cottin V, et al. Lung function outcomes in the INPULSIS(®) trials of nintedanib in Idiopathic Pulmonary Fibrosis. Respir Med. 2019;146:42–48.
   PubMed Web of Science ®Google Scholar
• Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with Idiopathic Pulmonary Fibrosis and preserved lung volume. Thorax. 2017;72(4):340.
   PubMed Web of Science ®Google Scholar
• Karimi-Shah BA, Chowdhury BA. Forced vital capacity in Idiopathic Pulmonary Fibrosis–FDA review of pirfenidone and nintedanib. N Engl J Med. 2015 Mar 26;372(13):1189–1191.
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced Idiopathic Pulmonary Fibrosis. Respir Res. 2019;20(1):55.
   PubMedGoogle Scholar
• Kolb M, Raghu G, Wells AU, et al. Nintedanib plus sildenafil in patients with Idiopathic Pulmonary Fibrosis. N Engl J Med. 2018 Nov 01;379(18):1722–1731.
   PubMed Web of Science ®Google Scholar
• Costabel U, Albera C, Lancaster LH, et al. An open-label study of the long-term safety of pirfenidone in patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 2017;94(5):408–415.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with Idiopathic Pulmonary Fibrosis. Thorax. 2016 May;71(5):429–435.
   PubMed Web of Science ®Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in Idiopathic Pulmonary Fibrosis. Eur Respir J. 2015;45(5):1382.
   PubMed Web of Science ®Google Scholar
• Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in Idiopathic Pulmonary Fibrosis. results of the INJOURNEY trial. Am J Respir Crit Care Med. 2017;197(3):356–363. 2018 Feb 01.
   Web of Science ®Google Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with Idiopathic Pulmonary Fibrosis. J Thorac Cardiovasc Surg. 2003 Aug;126(2):469–475.
   PubMed Web of Science ®Google Scholar
• Yusen RD, Edwards LB, Dipchand AI, et al. The registry of the international society for heart and lung transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant. J heart lung trans: off publ Int Soc Heart Trans. 2016 Oct;35(10):1170–1184.
   PubMed Web of Science ®Google Scholar
• King CS, Khandhar S, Burton N, et al. Native lung complications in single-lung transplant recipients and the role of pneumonectomy. J heart lung trans: off publ Int Soc Heart Trans. 2009 Aug;28(8):851–856.
   PubMed Web of Science ®Google Scholar
• Laporta Hernandez R, Aguilar Perez M, Lázaro Carrasco MT, et al. Lung transplantation in Idiopathic Pulmonary Fibrosis. Med Sci (Basel). 2018;6(3):68.
   Google Scholar
• Hu X, Lee JS, Pianosi PT, et al. Aspiration-related pulmonary syndromes. Chest. 2015 Mar;147(3):815–823.
   PubMed Web of Science ®Google Scholar
• Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900–1920. quiz 1943.
   PubMed Web of Science ®Google Scholar
• Johannson KA, Strambu I, Ravaglia C, et al. Antacid therapy in Idiopathic Pulmonary Fibrosis: more questions than answers? Lancet Respir Med. 2017 Jul;5(7):591–598.
   PubMed Web of Science ®Google Scholar
• Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in Idiopathic Pulmonary Fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013 Jul;1(5):369–376.
   PubMed Web of Science ®Google Scholar
• Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in Idiopathic Pulmonary Fibrosis: a pooled analysis. Lancet Respir Med. 2016 May;4(5):381–389.
   PubMed Web of Science ®Google Scholar
• Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of Idiopathic Pulmonary Fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018;6(9):707–714.
   PubMed Web of Science ®Google Scholar
• Mejia M, Carrillo G, Rojas-Serrano J, et al. Idiopathic Pulmonary Fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest. 2009 Jul;136(1):10–15.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in Idiopathic Pulmonary Fibrosis. Chest. 2013 Jul;144(1):234–240.
   PubMed Web of Science ®Google Scholar
• Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of Idiopathic Pulmonary Fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2016;195(1):78–85. 2017 Jan 01.
   Web of Science ®Google Scholar
• Caminati A, Lonati C, Cassandro R, et al. Comorbidities in Idiopathic Pulmonary Fibrosis: an underestimated issue. Eur Respir Rev. 2019;28(153):190044.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Abbritti M, Ley B, et al. Cough predicts prognosis in Idiopathic Pulmonary Fibrosis. Respirology. 2011 Aug;16(6):969–975.
   PubMed Web of Science ®Google Scholar
• Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Nov 3;380(9853):1583–1589.
   PubMed Web of Science ®Google Scholar
• Morice AH, Fontana GA, Belvisi MG, et al. ERS guidelines on the assessment of cough. Eur Respir J. 2007 Jun;29(6):1256–1276.
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Afzal A, Kitt MM, et al. The treatment of chronic cough in Idiopathic Pulmonary Fibrosis patients with gefapixant, a P2x3 receptor antagonist. B17. advances in ild therapy. Am Thorac Soc Int Conf Abstr: Am Thorac Soc. 2019; A2638–A2638. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2638
   Google Scholar
• Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in Idiopathic Pulmonary Fibrosis: a randomized trial. Ann Intern Med. 2012 Sep 18;157(6):398–406.
   PubMed Web of Science ®Google Scholar
• Lutherer LO, Nugent KM, Schoettle BW, et al. Low-dose oral interferon alpha possibly retards the progression of Idiopathic Pulmonary Fibrosis and alleviates associated cough in some patients. Thorax. 2011 May;66(5):446–447.
   PubMed Web of Science ®Google Scholar
• Azuma A, Taguchi Y, Ogura T, et al. Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with Idiopathic Pulmonary Fibrosis as benefiting from treatment. Respir Res. 2011;12(1):143.
   PubMedGoogle Scholar
• Kahn N, Fregonese L, Barrecheguren M, et al. Clinical highlights from the 2016 European respiratory society international congress. ERJ Open Res. 2017;3(2):00147–2016.
   PubMedGoogle Scholar
• Madison JM, Irwin RS. Chronic cough in adults with interstitial lung disease. Curr Opin Pulm Med. 2005 Sep;11(5):412–416.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic Pulmonary Fibrosis. Lancet. 2017 May 13;389(10082):1941–1952.
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic Pulmonary Fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 Mar 15;183(6):788–824.
   PubMed Web of Science ®Google Scholar
• Sharp C, Adamali H, Millar AB. Ambulatory and short-burst oxygen for interstitial lung disease. Cochrane Database Syst Rev. 2016 Jul;6(7):Cd011716.
   Google Scholar
• Schaeffer MR, Ryerson CJ, Ramsook AH, et al. Effects of hyperoxia on dyspnoea and exercise endurance in fibrotic interstitial lung disease. Eur Respir J. 2017 May;49(5):1602494.
   PubMed Web of Science ®Google Scholar
• Dowman LM, McDonald CF, Bozinovski S, et al. Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in Idiopathic Pulmonary Fibrosis patients without resting hypoxaemia. Respirology. 2017 Jul;22(5):957–964.
   PubMed Web of Science ®Google Scholar
• Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med. 2018 Oct;6(10):759–770.
   PubMed Web of Science ®Google Scholar
• Kohberg C, Andersen CU, Bendstrup E. Opioids: an unexplored option for treatment of dyspnea in IPF. Eur Clin Respir J. 2016 Jan 01;3(1):30629.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Ahmad S, et al. Serial Development of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis. Respiration. 2008;76(3):288–294.
   PubMed Web of Science ®Google Scholar
• Judge EP, Fabre A, Adamali HI, et al. Acute exacerbations and pulmonary hypertension in advanced Idiopathic Pulmonary Fibrosis. Eur Respir J. 2012 Jul;40(1):93–100.
   PubMed Web of Science ®Google Scholar
• Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in Idiopathic Pulmonary Fibrosis. J Clin Sleep Med. 2013 Jun 15;9(6):593–601.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Ahmad S, et al. Pulmonary hypertension and pulmonary function testing in Idiopathic Pulmonary Fibrosis. Chest. 2007 Mar;131(3):657–663.
   PubMed Web of Science ®Google Scholar
• Swigris JJ, Olson AL, Shlobin OA, et al. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with Idiopathic Pulmonary Fibrosis. Respirology. 2011 Apr;16(3):439–445.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Behr J, Brown KK, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2008 Jan 1;177(1):75–81.
   PubMed Web of Science ®Google Scholar
• Raghu G, Behr J, Brown KK, et al. Treatment of Idiopathic Pulmonary Fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013 May 7;158(9):641–649.
   PubMed Web of Science ®Google Scholar
• Nathan SD, Behr J, Cottin V, et al. Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy? Respir Med. 2017 Jan;122(Suppl 1):S10–s13.
   PubMedGoogle Scholar
• Han MK, Bach DS, Hagan PG, et al. Sildenafil preserves exercise capacity in patients with Idiopathic Pulmonary Fibrosis and right-sided ventricular dysfunction. Chest. 2013 Jun;143(6):1699–1708.
   PubMed Web of Science ®Google Scholar
• Tahara M, Oda K, Yamasaki K, et al. Temporal echocardiographic assessment of pulmonary hypertension in Idiopathic Pulmonary Fibrosis patients treated with nintedanib with or without oxygen therapy. BMC Pulm Med. 2019 Aug 22;19(1):157.
   PubMed Web of Science ®Google Scholar
• Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer. 2004;91 Suppl 2(Suppl2):S3–S10.
   PubMedGoogle Scholar
• Tzouvelekis A, Karampitsakos T, Gomatou G, et al. Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. Pulm Pharmacol Ther. 2020 Feb;60:101880.
   PubMed Web of Science ®Google Scholar
• Han S, Lee YJ, Park JS, et al. Prognosis of non-small-cell lung cancer in patients with Idiopathic Pulmonary Fibrosis. Sci Rep. 2019 Aug 29;9(1):12561.
   PubMedGoogle Scholar
• Kanayama M, Mori M, Matsumiya H, et al. Perioperative pirfenidone treatment for lung cancer patients with Idiopathic Pulmonary Fibrosis. Surg Today. 2020 May;50(5):469–474.
   PubMed Web of Science ®Google Scholar
• Sato T, Kondo H, Watanabe A, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg. 2015 Mar;63(3):164–172.
   PubMed Web of Science ®Google Scholar
• Ono T, Hareyama M, Nakamura T, et al. The clinical results of proton beam therapy in patients with Idiopathic Pulmonary Fibrosis: a single center experience. Radiat Oncol. 2016;11(1):56.
   PubMedGoogle Scholar
• Han S, Lee YJ, Park JS, et al. Prognosis of non-small-cell lung cancer in patients with Idiopathic Pulmonary Fibrosis. Sci Rep. 2019;9(1):12561.
   PubMedGoogle Scholar
• Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of Idiopathic Pulmonary Fibrosis. An international working group report. Am J Respir Crit Care Med. 2016 Aug 01;194(3):265–275.
   PubMed Web of Science ®Google Scholar
• Ryerson CJ, Cottin V, Brown KK, et al. Acute exacerbation of Idiopathic Pulmonary Fibrosis: shifting the paradigm. Eur Respir J. 2015 Aug;46(2):512–520.
   PubMed Web of Science ®Google Scholar
• Luca N, Roberto R, Federica De G, et al. Corticosteroid and cyclophosphamide in acute exacerbation of Idiopathic Pulmonary Fibrosis: a single center experience and literature review. Sarcoidosis vasculitis diffuse lung dis. 2016 Dec 23;33(4):385–391.
   Web of Science ®Google Scholar
• Akira M, Kozuka T, Yamamoto S, et al. Computed tomography findings in acute exacerbation of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2008 Aug 15;178(4):372–378.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in Idiopathic Pulmonary Fibrosis. N Engl J Med. 2011 Sep 22;365(12):1079–1087.
   PubMed Web of Science ®Google Scholar
• van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am J Respir Crit Care Med. 2010 Dec 1;182(11):1419–1425.
   PubMed Web of Science ®Google Scholar
• van Moorsel CHM, Ten Klooster L, van Oosterhout MFM, et al. SFTPA2 mutations in familial and sporadic idiopathic interstitial Pneumonia. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1249–1252.
   PubMed Web of Science ®Google Scholar
• Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009 Jan;84(1):52–59.
   PubMed Web of Science ®Google Scholar
• Young LR, Gulleman PM, Bridges JP, et al. The alveolar epithelium determines susceptibility to lung fibrosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med. 2012 Nov 15;186(10):1014–1024.
   PubMed Web of Science ®Google Scholar
• Hill C, Li J, Liu D, et al. Autophagy inhibition-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. Cell Death Dis. 2019 Aug 07;10(8):591.
   PubMed Web of Science ®Google Scholar
• Upagupta C, Shimbori C, Alsilmi R, et al. Matrix abnormalities in pulmonary fibrosis. Eur Respir Rev. 2018;27(148):180033.
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic Idiopathic Pulmonary Fibrosis. an integral model. Am J Respir Crit Care Med. 2014 May 15;189(10):1161–1172.
   PubMed Web of Science ®Google Scholar
• Thannickal VJ. Mechanistic links between aging and lung fibrosis. Biogerontology. 2013 Dec;14(6):609–615.
   PubMed Web of Science ®Google Scholar
• Ponticos M, Holmes AM, Shi-wen X, et al. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheumatism. 2009 Jul;60(7):2142–2155.
   PubMed Web of Science ®Google Scholar
• Duncan MR, Frazier KS, Abramson S, et al. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. Faseb J. 1999 Oct;13(13):1774–1786.
   PubMed Web of Science ®Google Scholar
• Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001;17(6):1220.
   PubMed Web of Science ®Google Scholar
• Raghu G, Scholand MB, de Andrade J, et al. FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in Idiopathic Pulmonary Fibrosis. Eur Respir J. 2016;47(5):1481.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for Idiopathic Pulmonary Fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 8(1):25–33.
   Google Scholar
• Oikonomou N, Mouratis MA, Tzouvelekis A, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012 Nov;47(5):566–574.
   PubMed Web of Science ®Google Scholar
• Maher TM, van der Aar EM, Van de Steen O, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat Idiopathic Pulmonary Fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018 Aug;6(8):627–635.
   PubMed Web of Science ®Google Scholar
• Kuttruff CA, Ferrara M, Bretschneider T, et al. Discovery of BI-2545: A novel autotaxin inhibitor that significantly reduces LPA levels in Vivo. ACS Med Chem Lett. 2017 Dec 14;8(12):1252–1257.
   PubMed Web of Science ®Google Scholar
• Nikolaou A, Kokotou MG, Limnios D, et al. Autotaxin inhibitors: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Jul 03;27(7):815–829.
   PubMed Web of Science ®Google Scholar
• Palmer SM, Snyder L, Todd JL, et al. Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018 Nov;154(5):1061–1069.
   PubMed Web of Science ®Google Scholar
• Kulkarni AB, Huh CG, Becker D, et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):770–774.
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. A mechanism for regulating pulmonary inflammation and fibrosis: the integrin αvβ6 binds and activates latent TGF β1. Cell. 1999;96(3):319–328.
   PubMed Web of Science ®Google Scholar
• Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110(6):673–687.
   PubMed Web of Science ®Google Scholar
• Munger JS, Huang X, Kawakatsu H, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 1999 Feb 5;96(3):319–328.
   PubMed Web of Science ®Google Scholar
• Chen H, Qu J, Huang X, et al. Mechanosensing by the alpha6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Nat Commun. 2016 Aug 18;7(1):12564.
   PubMedGoogle Scholar
• Kitamura H, Cambier S, Somanath S, et al. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin alphavbeta8-mediated activation of TGF-beta. J Clin Invest. 2011 Jul;121(7):2863–2875.
   PubMed Web of Science ®Google Scholar
• Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008 Jan 1;177(1):56–65.
   PubMed Web of Science ®Google Scholar
• Maden CH, Fairman D, Chalker M, et al. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin alphavbeta6 inhibitor, in healthy participants. Eur J Clin Pharmacol. 2018 Jun;74(6):701–709.
   PubMed Web of Science ®Google Scholar
• Nakagawa N, Barron L, Gomez IG, et al. Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease. JCI Insight. 2016;1(20):e87446–e87446.
   PubMed Web of Science ®Google Scholar
• Pilling D, Roife D, Wang M, et al. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol. 2007;179(6):4035.
   PubMed Web of Science ®Google Scholar
• van den Blink B, Dillingh MR, Ginns LC, et al., Recombinant human pentraxin-2 therapy in patients with Idiopathic Pulmonary Fibrosis: safety, pharmacokinetics and exploratory efficacy. Eur Respir J. 2016;47(3): 889.
   PubMed Web of Science ®Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with Idiopathic Pulmonary Fibrosis: A randomized clinical trial. JAMA. 2018;319(22):2299–2307.
   PubMed Web of Science ®Google Scholar
• Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with Idiopathic Pulmonary Fibrosis: an open-label extension study. Lancet Respir Med. 2019;7(8):657–664.
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012 Mar 1;185(5):537–546.
   PubMed Web of Science ®Google Scholar
• MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol. 2008 Feb 15;180(4):2650–2658.
   PubMed Web of Science ®Google Scholar
• Hirani N, Mackinnon A, Nicol L, et al. TD139, A novel inhaled galectin-3 inhibitor for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from the first in (IPF) patients study. A24. IPF: Clinical studies, therapeutics, and more I. Am Thorac Soc Int Conf Abstr: Am Thorac Soc. 2017; A7560–A7560.
   Google Scholar
• Gagnon L, Leduc M, Thibodeau J-F, et al. A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84. Am J Pathol. 2018;188(5):1132–1148.
   PubMed Web of Science ®Google Scholar
• Coussens L, Parker PJ, Rhee L, et al. Multiple, distinct forms of bovine and human protein kinase C suggest diversity in cellular signaling pathways. Science (New York, NY). 1986 Aug 22;233(4766):859–866.
   Google Scholar
• Fabbro D, Cowan-Jacob SW, Moebitz H. Ten things you should know about protein kinases: IUPHAR Review 14. Br J Pharmacol. 2015 Jun;172(11):2675–2700.
   PubMed Web of Science ®Google Scholar
• Beyer C, Distler JHW. Tyrosine kinase signaling in fibrotic disorders: translation of basic research to human disease. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2013 Jul 01;1832(7):897–904.
   PubMed Web of Science ®Google Scholar
• Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of Idiopathic Pulmonary Fibrosis. Eur Respir J. 2015;45(5):1434.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for Idiopathic Pulmonary Fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010 Mar 15;181(6):604–610.
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Gabrielli B, Pomponio G, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014 Jul 8;16(4):R144.
   PubMed Web of Science ®Google Scholar
• Khanna D, Saggar R, Mayes MD, et al. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheumatism. 2011 Nov;63(11):3540–3546.
   PubMedGoogle Scholar
• Pope J, McBain D, Petrlich L, et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheumatism. 2011 Nov;63(11):3547–3551.
   PubMed Web of Science ®Google Scholar
• Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis. 2011;70(6):1003–1009.
   PubMed Web of Science ®Google Scholar
• Alcorn JF, van der Velden J, Brown AL, et al. c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2009 Apr;40(4):422–432.
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Ye Y, Nolin JD, et al. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin Transl Med. 2016 Dec;5(1):36.
   PubMedGoogle Scholar
• Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015;67(1):103–117.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest. 2013 Mar;123(3):1096–1108.
   PubMed Web of Science ®Google Scholar
• Knipe RS, Probst CK, Lagares D, et al. The rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis. Am J Respir Cell Mol Biol. 2018 Apr;58(4):471–481.
   PubMed Web of Science ®Google Scholar
• O’Dwyer DN, Dickson RP, Moore BB. The lung microbiome, immunity, and the pathogenesis of chronic lung disease. J Immunol. 2016;196(12):4839–4847.
   PubMed Web of Science ®Google Scholar
• Molyneaux PL, Cox MJ, Willis-Owen SAG, et al. The role of bacteria in the pathogenesis and progression of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2014;190(8):906–913.
   PubMed Web of Science ®Google Scholar
• Han MK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in Idiopathic Pulmonary Fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014 Jul;2(7):548–556.
   PubMed Web of Science ®Google Scholar
• Shulgina L, Cahn AP, Chilvers ER, et al. Treating Idiopathic Pulmonary Fibrosis with the addition of co-trimoxazole: a randomised controlled trial. Thorax. 2013;68(2):155.
   PubMed Web of Science ®Google Scholar
• Macaluso C, Furcada JM, Alzaher O, et al. The potential impact of azithromycin in Idiopathic Pulmonary Fibrosis. Eur Respir J 2019;53:1800628.
   Google Scholar
• Hammond M, Clark AB, Cahn AP, et al. The efficacy and mechanism evaluation of treating Idiopathic Pulmonary Fibrosis with the addition of co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials. 2018 Feb 5;19(1):89.
   PubMedGoogle Scholar
• Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411–419.
   PubMed Web of Science ®Google Scholar
• Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med. 2018 Jun;85(6):459–467.
   PubMed Web of Science ®Google Scholar
• Clement A, Nathan N, Epaud R, et al. Interstitial lung diseases in children. Orphanet J Rare Dis. 2010;5(1):22.
   PubMedGoogle Scholar
• Liu L, Ren J, He Z, et al. Cholesterol-modified Hydroxychloroquine-loaded nanocarriers in bleomycin-induced pulmonary fibrosis. Sci Rep. 2017 Sep 06;7(1):10737.
   PubMedGoogle Scholar
• Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for Idiopathic Pulmonary Fibrosis: a fleischner society white paper. Lancet Respir Med. 2018 Feb;6(2):138–153.
   PubMed Web of Science ®Google Scholar
• Walsh SLF, Lederer DJ, Ryerson CJ, et al. Diagnostic likelihood thresholds that define a working diagnosis of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Nov 01;200(9):1146–1153.
   PubMed Web of Science ®Google Scholar
• Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019 Oct 31;381(18):1718–1727.
   PubMed Web of Science ®Google Scholar
• Jacob J, Bartholmai BJ, Rajagopalan S, et al. Predicting outcomes in Idiopathic Pulmonary Fibrosis using automated computed tomographic analysis. Am J Respir Crit Care Med. 2018 Sep 15;198(6):767–776.
   PubMed Web of Science ®Google Scholar
• Wells AU. Pamrevlumab in Idiopathic Pulmonary Fibrosis. Lancet Respir Med. 2020 Jan;8(1):2–3.
   PubMed Web of Science ®Google Scholar
• Kokosi MA, Margaritopoulos GA, Wells AU. Personalised medicine in interstitial lung diseases. Eur Respir Rev. 2018;27(148):170117.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in Idiopathic Pulmonary Fibrosis. Respirology. 2006 Mar;11(2):164–168.
   PubMed Web of Science ®Google Scholar
• Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for Idiopathic Pulmonary Fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017 Dec;5(12):946–955.
   PubMed Web of Science ®Google Scholar
• Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with Idiopathic Pulmonary Fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7(9):771–779.
   PubMed Web of Science ®Google Scholar